Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $45.14

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $45.1429.

Several analysts have recently commented on ORKA shares. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 12th. BTIG Research raised their price objective on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Guggenheim initiated coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They set a “buy” rating and a $60.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Viking Global Investors LP bought a new position in Oruka Therapeutics in the third quarter valued at about $51,280,000. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics during the 3rd quarter worth about $25,640,000. Deep Track Capital LP lifted its position in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares during the period. Braidwell LP boosted its stake in shares of Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock valued at $16,133,000 after purchasing an additional 424,750 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Oruka Therapeutics by 100.6% during the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after buying an additional 354,821 shares during the period. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Up 3.0%

NASDAQ:ORKA opened at $28.26 on Monday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -10.06 and a beta of -0.30. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $29.98. The firm has a 50 day moving average of $23.33 and a 200-day moving average of $16.61.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.